Developing groundbreaking therapeutics for patients with life-threatening cancers

Advancing targeted oncolytic immunotherapies to address patient need

Bringing hope to patients who need improved treatments for solid tumors

Our Focus
  • Jennerex is focused on the development and commercialization of targeted oncolytic immunotherapies for solid tumors. Our lead product, Pexa-Vec (JX-594), is a proprietary, oncolytic immunotherapy designed to attack cancer through three diverse mechanisms of action. See how it works.

    Pexa-vec border=

    Watch how it works.
Our Progress